Premium
Hydrodynamic Isotonic Fluid Delivery Ameliorates Moderate Ischemia/Reperfusion Injury in Rat Kidneys
Author(s) -
Corridon Peter,
Rhodes George,
Atkinson Simon,
Bacalla Robert
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.807.7
Subject(s) - medicine , hypervolemia , creatinine , diuresis , renal function , ischemia , transplantation , anesthesia , reperfusion injury , kidney , intravascular volume status , urology , cardiology , blood volume , hemodynamics
Highly aerobic organs like the kidney are innately susceptible to ischemia/reperfusion injury (IRI), which can originate from sources like myocardial infarction, and renal trauma and transplantation. Current therapy is mainly supportive and depends on the underlying cause(s) of damage. In the absence of hypervolemia, intravenous fluid delivery is oftentimes the first course of treatment. This approach is employed to prevent or eliminate volume depletion, ameliorate tubular blockage, dilute nephrotoxins, facilitate diuresis and restore normal glomerular filtration rates. We investigated the therapeutic potential of a relatively low volume (0.5 ml) hydrodynamic isotonic fluid delivery (HIFD) to the left renal vein 1 and 24 hours after inducing moderate IRI. This model consisted of first subjecting live rats to bilateral renal pedicle cross‐clamps for 30 minutes and HIFD only to the left kidney at the given time points after reperfusion. Strikingly HIFD at the 24‐hour mark produced substantial and statistically significant (p‐value = 0.02) decreases in serum creatinine as compared to untreated animals. Relative changes in creatinine were also significantly (p‐value = 0.03) after HIFD at the 1‐hour time point. HIFD also provided at the each time point mediated a return to baseline creatinine levels within 2 days of the initial insult. The potential therapeutic benefit observed in these results provides an exciting platform to facilitate the future management of ischemia‐reperfusion injuries using in a single infusion technique.